[go: up one dir, main page]

RU2019114940A3 - - Google Patents

Download PDF

Info

Publication number
RU2019114940A3
RU2019114940A3 RU2019114940A RU2019114940A RU2019114940A3 RU 2019114940 A3 RU2019114940 A3 RU 2019114940A3 RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A3 RU2019114940 A3 RU 2019114940A3
Authority
RU
Russia
Application number
RU2019114940A
Other versions
RU2019114940A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019114940(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2019114940A publication Critical patent/RU2019114940A/ru
Publication of RU2019114940A3 publication Critical patent/RU2019114940A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02Carbamic acids; Salts of carbamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2019114940A 2013-03-13 2014-03-12 Лечение катаплексии RU2019114940A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
US61/778,998 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015143610A Division RU2689984C2 (ru) 2013-03-13 2014-03-12 Лечение катаплексии

Publications (2)

Publication Number Publication Date
RU2019114940A RU2019114940A (ru) 2019-06-28
RU2019114940A3 true RU2019114940A3 (ru) 2019-12-25

Family

ID=51530017

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019114940A RU2019114940A (ru) 2013-03-13 2014-03-12 Лечение катаплексии
RU2015143610A RU2689984C2 (ru) 2013-03-13 2014-03-12 Лечение катаплексии

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015143610A RU2689984C2 (ru) 2013-03-13 2014-03-12 Лечение катаплексии

Country Status (21)

Country Link
US (7) US9359290B2 (ru)
EP (1) EP2968208B1 (ru)
JP (2) JP6530741B2 (ru)
KR (1) KR102192554B1 (ru)
CN (1) CN105431142B (ru)
AU (1) AU2014248849B2 (ru)
BR (1) BR112015022197B1 (ru)
CA (1) CA2905457A1 (ru)
DK (1) DK2968208T3 (ru)
ES (1) ES2927675T3 (ru)
HR (1) HRP20221018T1 (ru)
HU (1) HUE060060T2 (ru)
MX (1) MX381381B (ru)
MY (1) MY177740A (ru)
PH (1) PH12015502075A1 (ru)
PT (1) PT2968208T (ru)
RU (2) RU2019114940A (ru)
SG (1) SG11201507121RA (ru)
SI (1) SI2968208T1 (ru)
TW (2) TWI684450B (ru)
WO (1) WO2014164969A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201328689A (zh) * 2005-06-08 2013-07-16 Sk Biopharmaceuticals Co Ltd 治療睡眠-覺醒病症之方法
CN106727486A (zh) * 2009-06-22 2017-05-31 爱思开生物制药株式会社 治疗或预防疲劳的方法
KR102192554B1 (ko) * 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료
WO2015010014A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN109996540A (zh) 2016-09-06 2019-07-09 爵士制药国际Iii有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯的溶剂化物形式
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
US10710958B2 (en) 2016-10-06 2020-07-14 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol compounds and uses thereof
MY203401A (en) 2017-06-02 2024-06-26 Jazz Pharmaceuticals Ireland Ltd Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
CR20210514A (es) * 2018-10-15 2021-11-12 Axsome Therapeutics Inc USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
PE20230181A1 (es) * 2019-12-03 2023-02-01 Axsome Therapeutics Inc Uso de reboxetina para tratar los trastornos del sistema nervioso
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
JP4068154B2 (ja) 1996-10-10 2008-03-26 エス ケー コーポレイション O―カルバモイル―フェニルアラニノール化合物とその薬剤学的に有用な塩及びその製造方法
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1771432B1 (en) * 2004-03-31 2010-12-08 Janssen Pharmaceutica NV Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
KR20070100686A (ko) * 2004-09-07 2007-10-11 오르펀 메디칼, 인크. 개선된 ghb 조성물
MX2007005172A (es) 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
TW201328689A (zh) 2005-06-08 2013-07-16 Sk Biopharmaceuticals Co Ltd 治療睡眠-覺醒病症之方法
WO2007001841A1 (en) 2005-06-22 2007-01-04 Sk Holdings Co., Ltd. Treatment of sexual dysfunction
BRPI0520451A2 (pt) 2005-07-26 2009-05-12 Janssen Pharmaceutica Nv métodos para tratamento de distúrbios associados a substáncias quìmicas
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
JP2010506845A (ja) 2006-10-13 2010-03-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルアルキルアミノカルバメート組成物
JP2010510175A (ja) * 2006-11-10 2010-04-02 ディメリックス・バイオサイエンス・ピーティーワイ・リミテッド 甲状腺刺激ホルモン放出ホルモン受容体−オレキシン受容体のヘテロダイマー/オリゴマー
CN106727486A (zh) 2009-06-22 2017-05-31 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316172B2 (en) 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
CA2779457C (en) 2009-11-06 2017-10-17 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102192554B1 (ko) * 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료

Also Published As

Publication number Publication date
TWI684450B (zh) 2020-02-11
DK2968208T3 (da) 2022-08-22
SG11201507121RA (en) 2015-10-29
EP2968208A4 (en) 2016-10-12
US9585863B2 (en) 2017-03-07
BR112015022197B1 (pt) 2022-06-07
BR112015022197A8 (pt) 2019-11-26
ES2927675T3 (es) 2022-11-10
AU2014248849B2 (en) 2018-08-30
US20190218174A1 (en) 2019-07-18
PT2968208T (pt) 2022-10-28
US9359290B2 (en) 2016-06-07
US20250059135A1 (en) 2025-02-20
EP2968208B1 (en) 2022-07-20
KR102192554B1 (ko) 2020-12-18
US20140275244A1 (en) 2014-09-18
SI2968208T1 (sl) 2023-02-28
BR112015022197A2 (pt) 2017-07-18
TW201513856A (zh) 2015-04-16
RU2015143610A (ru) 2017-04-20
MY177740A (en) 2020-09-23
RU2689984C2 (ru) 2019-05-30
EP2968208A1 (en) 2016-01-20
CN105431142A (zh) 2016-03-23
US12162821B2 (en) 2024-12-10
HUE060060T2 (hu) 2023-01-28
US11072579B2 (en) 2021-07-27
CN105431142B (zh) 2019-04-26
US20160250176A1 (en) 2016-09-01
JP6530741B2 (ja) 2019-06-12
RU2019114940A (ru) 2019-06-28
AU2014248849A1 (en) 2015-10-08
US20170137375A1 (en) 2017-05-18
RU2015143610A3 (ru) 2018-03-21
MX381381B (es) 2025-03-12
TW201919606A (zh) 2019-06-01
KR20150139522A (ko) 2015-12-11
HK1219236A1 (zh) 2017-03-31
CA2905457A1 (en) 2014-10-09
TWI663971B (zh) 2019-07-01
PH12015502075B1 (en) 2016-01-18
JP2016512531A (ja) 2016-04-28
US10259780B2 (en) 2019-04-16
MX2015012644A (es) 2016-06-21
JP2019147830A (ja) 2019-09-05
WO2014164969A1 (en) 2014-10-09
US20230416195A1 (en) 2023-12-28
US11713292B2 (en) 2023-08-01
HRP20221018T1 (hr) 2023-01-06
PH12015502075A1 (en) 2016-01-18
US20220017457A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
AP2016009275A0 (ru)
BR112015007533A2 (ru)
BR102016010778A2 (ru)
BR112014017733A2 (ru)
BR112014018502A2 (ru)
BR112014017739A2 (ru)
BR112014019326A2 (ru)
BR112014018480A2 (ru)
BR112014018516A2 (ru)
BR112014020341A2 (ru)
BR112014017855A2 (ru)
BR112014017765A2 (ru)
BR112014017669A2 (ru)
BR112014021878A2 (ru)
BR112016004523A2 (ru)
BR112014018468A2 (ru)
BR112014017901A2 (ru)
BR112014019204A2 (ru)
BR112014018207A2 (ru)
BR112015015948A2 (ru)
BR112014017722A2 (ru)
BR112014017653A2 (ru)
BR112014018578A2 (ru)
BR112014018483A2 (ru)
BR112014017794A2 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201012